MedTrace Logo

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

NCT04642365 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-05-21

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety, tolerability and preliminary anti-tumor activity of RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.

Conditions

Interventions

DRUG

RO7296682

RO7296682 will be administered as per the schedules specified in the respective arms.

DRUG

Atezolizumab

Atezolizumab will be administered as per the schedules specified in the respective arms.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2024-01-04
Completion
2024-01-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Denmark
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04642365 on ClinicalTrials.gov